Alcon Laboratories falsely claimed their eye products to be sterile. Here’s why it matters.

What This Actually Means for Your Eyes

Eye products are not like a mislabeled box of crackers. When you put a gel directly onto your eye, whatever is in that gel goes directly into one of the most vulnerable, infection-prone surfaces on your body. Your eyes have almost no barrier. There is no stomach acid to kill pathogens, no skin to keep things out. Anything in that tube goes straight in.

People who reach for Systane Night Gel or GenTeal Tears are already suffering. Dry eye disease is painful. It interrupts sleep. It makes screen time, reading, and driving miserable. These products are marketed specifically for nighttime use, which means people applied them right before closing their eyes and going to sleep, giving any contamination hours of uninterrupted contact with their ocular surface.

The mold species the FDA found at Excelvision are not harmless environmental spores. Fusarium oxysporum is one of the leading causes of fungal keratitis, a corneal infection that can progress to blindness. Aspergillus species cause similar infections. These are the organisms that ophthalmologists treat with aggressive antifungal medication for weeks, that sometimes require corneal transplants, and that in severe cases cannot be fully reversed. The FDA classifies this recall as Class II, meaning there is a reasonable probability that the products will cause “temporary or medically reversible adverse health consequences.” That is a regulatory way of saying: this could hurt you, probably not permanently, but possibly.

Nobody buying an eye gel at a CVS Pharmacy thinks to ask whether the sterility claim on the box is true. That trust, the fundamental assumption that a product labeled “STERILE” for use in your eyes has actually been verified as sterile, is exactly what Alcon is accused of exploiting.

Legal Receipts: What the Documents Actually Say

The Timeline of Negligence

The gap between when contamination was first documented and when consumers were protected is the core indictment here.

Public Deception: The Label Said One Thing. The Factory Was Another.

The gap between what Alcon communicated to consumers and what its own manufacturing facility reflected is direct and documented.

• The packaging for both Systane Night Gel and GenTeal Tears Lubricant Eye Gel prominently states “STERILE.” The complaint alleges this representation induced consumers to pay a premium price, with the expectation that the products met the manufacturing standard that word implies.
• The FDA’s Warning Letter to Excelvision, issued following the November 2024 inspection, documented egregious violations of Current Good Manufacturing Practice regulations. These violations directly compromised the sterility assurance that the “STERILE” label communicated to every buyer.
• Consumers had no ability to independently verify whether the product was sterile. The complaint states that the only way a consumer could have discovered the truth was to send the product off to a laboratory for extensive testing. Alcon possessed all the relevant knowledge about conditions at Excelvision. Consumers possessed none of it.
• The complaint alleges that Alcon’s misrepresentations were “willfully, wantonly, and with reckless disregard for the truth,” and that the company knowingly intended for consumers to pay a premium based on the sterility claim.

Supply Chain Complicity: The French Factory Problem

The contamination problem was not inside Alcon’s own facilities. It was inside a contract manufacturer in France, which is exactly the kind of corporate structure that allows companies to profit from a product while pointing to someone else when something goes wrong.

• Both products, Systane Night Gel and GenTeal Tears Lubricant Eye Gel, were manufactured at the same third-party contract facility: Excelvision Fareva, located in France. This is not an Alcon-owned facility.
• The FDA’s Warning Letter was addressed to Excelvision, not Alcon. Yet Alcon owned the label, designed the packaging, collected the revenue, and is the party that sold consumers a product stamped “STERILE.”
• The complaint alleges that “Defendants are in the unique and superior position of knowing, or having the responsibility to know, the manufacturing conditions where the Products are processed.” Alcon chose Excelvision. Alcon had the contractual and legal obligation to ensure what came out of that facility matched what went on the label.
• The use of a contract manufacturer in a foreign jurisdiction creates a diffusion of accountability across borders. Consumers in the United States have no visibility into a French factory. The FDA’s reach into foreign manufacturing facilities is limited and inspection-dependent. Alcon was the entity with real-time access and contractual authority.
• The FDA inspection took place in November 2024 and documented conditions including a mold history going back to 2022. The recall was not issued until April 2026. The complaint does not document what Alcon’s internal quality auditing of Excelvision looked like, but the FDA findings raise an obvious question about whether that auditing was adequate.

Outsource the Risk To Contractors, Keep the Revenue

Alcon’s use of Excelvision as a contract manufacturer is precisely the kind of arrangement that allows a brand owner to maintain plausible distance from production failures while retaining full control over the label, the pricing, and the profit.

• Alcon Laboratories and Alcon Research LLC are named as defendants, not Excelvision. The complaint makes clear that Alcon “manufacture[s], market[s], advertise[s], and distribute[s] the Products throughout the United States” and “created and/or authorized the false, misleading, and deceptive advertisements, packaging, and labeling.” Excelvision is the facility. Alcon is the responsible party.
• The complaint states that because Alcon “rel[ied] on this facility to produce the Products,” it was “in the unique and superior position of knowing, or having the responsibility to know, the manufacturing conditions where the Products are processed.” That responsibility cannot be contracted away. Alcon was the party with authority to audit Excelvision, to require corrective action, to halt production, and to change the label. None of those levers were pulled before the FDA forced a recall.
• By the time consumers received these products with a “STERILE” label, Alcon had already extracted payment. The price premium that consumers paid, based on the sterility claim, went to Alcon. The manufacturing deficiency at Excelvision did not reduce what consumers paid. It reduced only what consumers received.

Profit-Maximization at All Costs

The complaint documents a direct financial incentive underlying Alcon’s sterility claim, one that the lawsuit argues Alcon consciously maintained while possessing or being required to possess knowledge of manufacturing failures.

• The complaint alleges that Alcon “knew and intended that consumers would pay a premium for a product marketed as sterile over comparable products not so marketed.” The sterility label was a price-support mechanism. Remove the label, reduce the premium. The label stayed on.
• The complaint states that if Alcon had disclosed the lack of sterility assurance, “Plaintiff and the Class would not have purchased the Products, or, at the very least, would not have paid nearly as much for the Products.” The financial benefit of the omission was not incidental. It was the direct result of the omission.
• The total amount in controversy in the class action exceeds $5,000,000, representing the aggregate price premium paid by thousands of consumers across the United States for a product that the FDA ultimately recalled for lacking sterility assurance.
• The complaint characterizes the products as “worthless” as labeled because the core attribute consumers paid for, sterility, could not be assured. The product was not worth less than advertised. It was, per the complaint, worth nothing as the product it claimed to be.

Societal Impact Mapping

Public Health

• Non-sterile ophthalmic products pose a direct risk of introducing bacteria and fungi into the eye, a body surface with almost no natural barrier against infection. The FDA classifies the recall as Class II, meaning products may cause “temporary or medically reversible adverse health consequences,” while acknowledging a low probability but non-zero risk of serious harm.
• The specific mold species found at Excelvision, Fusarium oxysporum and Aspergillus in particular, are documented causes of fungal keratitis, a corneal infection that can result in permanent vision impairment if not caught and aggressively treated. These are not low-risk organisms.
• The products were designed for nighttime use. Consumers applied them immediately before sleep, which means any contamination had extended, uninterrupted contact with the ocular surface without the natural protective mechanism of blinking. The use case maximized exposure duration.
• Consumers with compromised immune systems, pre-existing eye conditions, or who had recently undergone eye surgery face an elevated risk from non-sterile ocular products. The complaint does not document specific cases of injury, but the complaint establishes the risk was real and known to regulators.

Economic Inequality

• Dry eye disease disproportionately affects older adults and people with chronic conditions, many of whom are on fixed incomes. These consumers are less able to absorb the financial loss of paying a premium for a recalled product and less equipped to navigate refund processes, regulatory complaints, or litigation.
• The complaint establishes that the injury was the price premium paid over a comparable non-sterile product. For consumers who purchased multiple units over time, relying on these products as part of a regular eye care regimen, that premium accumulates into a meaningful financial harm.
• The class action is specifically designed to aggregate individual claims that are too small for any individual to litigate on their own. The complaint notes that “many members of the Class are without the financial resources necessary to pursue this matter” individually. The corporate structure, selling a modestly-priced consumer product at scale, creates a situation where diffuse harm across thousands of buyers becomes individually unactionable without collective litigation.
• Products were distributed through CVS Pharmacy locations nationwide. CVS is a primary healthcare access point for lower- and middle-income consumers who rely on pharmacy chains rather than specialty medical retailers. The distribution channel concentrated harm in a population with fewer resources to respond to it.

What a Recall Without Accountability Actually Looks Like

A recall is a regulatory mechanism. It does not compensate the people who already bought and used the product. It does not penalize the company that made the mislabeled claim. It simply asks for the remaining units back.

• The Class II recall was initiated by Alcon itself, at the FDA’s direction, following the Warning Letter to Excelvision. Initiating your own recall does not constitute accountability for the harm already caused by products sold with a false sterility label.
• Consumers who purchased these products before the April 2026 recall had no way of knowing they had been exposed to a product that lacked sterility assurance. The “STERILE” label they read at point of sale was the only information they had, and it was, according to the complaint, false.
• The recall notice reached retail stores and pharmacies. It did not reach the consumers who had already taken the product home, used it, and discarded the packaging. Those consumers, who bore the direct health and financial risk, were the least likely to be informed of the recall in time for it to matter.
• The complaint alleges violations of New York General Business Law Sections 349 and 350, breach of implied warranty of merchantability, negligence, and unjust enrichment. The prayer for relief requests compensatory, statutory, and punitive damages, as well as injunctive relief and disgorgement of all moneys obtained through the unlawful conduct. Whether any of that relief is ultimately awarded depends entirely on how this litigation proceeds.